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A Ab bs st tr ra ac ct t
Technological advances over the past several years have dramatically reduced the cost of whole-
genome sequencing. At the same time, understanding of the functional significance of genetic
variation has advanced considerably. The routine generation of whole-genome sequence data for
individual patients will soon be sufficiently cost-effective for widespread clinical integration. Yet,
the clinical utility of whole-genome data is currently limited by an inability to effectively process,
store, interpret and update genomic data, while at the same time protecting patient privacy. Enter
the electronic health record. We propose that without the integration of a dynamic uniform
electronic health record, counseling patients on the basis of genome-wide data will be futile.
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I In nt tr ro od du uc ct ti io on n
Personalized genetic medicine is near the top of the list for
every medical school and hospital planning committee. Not
only does it have the high-tech cache coveted by marketing
and development offices, but it is really thought to be a route
to better outcomes and cost reduction. The hope is that the
additional costs of genetic profiling will be more than offset
by the savings created by individualized treatment and
avoidance of predictable iatrogenic complications [1]. The
paths to discovery of the genetic determinants of common
disease are now on firm ground. Cost-effective complete
genome sequencing for individuals is very close [2,3].
However, the interpretation and application of the resulting
data now loom as critical challenges.
Enter the electronic health record (EHR). Successful
investigation and application begins with carefully specified
phenotypes. In medical practice, phenotypes are represented
in the records of patient encounters. Records of subjective
symptoms, measurements of physiological states like blood
pressure and weight, physical exam findings, results of
laboratory testing and imaging, and temporal changes in
activity of disease all have to be consistently and accurately
reflected in the medical record. In an ideal world all these
data would be: recorded with completeness using a common
vocabulary; available to all the healthcare providers; and
accompanied by protection of the privacy rights of the
individual patient. Hospital, county, state, and national
healthcare systems might also be able to access the data in
aggregate to inform decisions about what works at what cost.
Capturing, archiving, and retrieving all these data cannot be
accomplished without EHRs. Genetic data, while no more or
less complicated than other specialized clinical data, like
imaging, do present some special concerns [4]. For one
thing, once they are accurately collected, DNA results do not
change. New ethical and legal issues are clearly emerging not
only as a consequence of the requirements of the individual
patient, but also as a result of the system’s needs. At the
moment, these issues are practically related to acquisition of
data for research, but actual clinical application to individual
patient care is already beginning. How do we balance the
protection of the individual with the informational needs ofthe community? How do we minimize the burden of
genetic information while actively exploiting it for the
benefit of individuals?
P Pr ri iv va ac cy y   v ve er rs su us s   t th he e   g go ol ld d- -m mi in ne e   - -   r re es se ea ar rc ch h   c ca ap pt tu ur re e   o of f
e el le ec ct tr ro on ni ic c   h he ea al lt th h   r re ec co or rd d   i in nf fo or rm ma at ti io on n
Attempts to maximize data utility in the research context
have generally focused on broad data sharing [5,6]. Already,
massive amounts of genotypic data have been produced
from genome-wide association studies (GWAS) across the
globe. Archiving these data and making them available to
other researchers will provide a tremendous community
resource that will hopefully speed scientific discovery and
result in new medical advances. In the early days of genome
research, data were shared in publicly accessible databases,
such as the Single Nucleotide Polymorphism database
(dbSNP). Individual privacy was protected by removing
personally identifying information, including most clinical
information. However, ethical considerations related to the
fact that DNA is itself a unique identifier [7,8] called into
question the adequacy of public databases and led to the
creation of controlled-access databases, such as the database
of Genotypes and Phenotypes (dbGaP) in the United States
[9] and the European Genotype Archive in Europe [10].
These databases add a layer of protection to ensure that only
bona fide researchers can access participant data and only if
the research purpose is consistent with the participant’s
original consent. This heightened protection makes it a bit
more cumbersome for researchers to access individual-level
data, but it also presents an opportunity to increase the
utility of the data by linking it to certain clinical variables
and other phenotypic information.
Most GWAS collect and share only limited clinical data. This
significantly reduces the utility of individual genotypes and
limits the ability to study the functional significance of genetic
variation. Both ‘deep phenotyping’ (collecting extensive
phenotypic information at the outset of a study) [11] and
‘targeting phenotyping’ (re-contacting individual participants
to obtain additional phenotypic information as it is needed)
[12] have been proposed, but both of these methods are costly
and time consuming. To assess the alternative option of
linking genotypic data with the EHR, the Electronic Medical
Records and Genomics (eMERGE) Network was created and
funded by the National Institutes of Health (NIH). It consists
of five institutions in the United States that use data directly
from the EHR to propel genetic research [13].
Linking genotypic data to the EHR provides maximum
utility, but it also poses significant privacy risks for partici-
pants. These risks can be managed in several ways. The
academic model provides some privacy protection through
controlled-access databases, and manages residual risk
through the process of informed consent [14]. An alternative
approach is that of projects like the Personal Genome
Project (PGP), which promises no privacy protection and
recruits only those individuals who are comfortable sharing
their clinical information, including their genetic data, in a
public database [15]. Finally, at the other extreme are
companies like Private Access, Inc., which recently
partnered with Genetic Alliance to introduce a web-based
program that gives patients individualized control over who
can access their records and data [16]. Each of these
approaches has advantages and disadvantages, but they all
strive for the same thing: to maximize the scientific utility of
genetic information while respecting individual rights and
protecting patient privacy.
H Ho ow w   q qu ui ic ck kl ly y   w we e   f fo or rg ge et t   - -   c cl li in ni ic ca al l   a ap pp pl li ic ca at ti io on n   o of f   t th he e
p pe er rs so on na al l   g ge en no om mi ic c   p pr ro of fi il le e
It is difficult enough to link genetic information with the
EHR in research; integrating it in the clinical setting raises a
host of additional challenges. A quick glance at any list of
disease-associated single nucleotide polymorphisms (SNPs)
directly illustrates the problem. Physicians and patients
cannot fully retain the contents of the matrix consisting of
genes, alleles, diseases and probabilities. It will not be
feasible for individuals to update their information based on
the newest research results. The time-honored approach to
genetic counseling falters under the weight of thousands of
low-, medium-, and high-risk predictions for every single
person. Physicians and patients alike will be overwhelmed.
This is a problem well-matched to the capabilities of a
uniform EHR. The health record will not only accurately
retain large, complex genetic results, but we believe that
there will be an evolution of clinical practice guidelines into
active interpretive algorithms that incorporate genomic
information [17]. These algorithms will compute individual
risk and apply them to clinical decision support as needed.
The vast majority of the individual genetic data will be
latent, never really having any part in a person’s health
story. Real-time ‘research’ by dynamic monitoring of inter-
ventions and outcomes in large clinic populations will
facilitate more rapid recognition of important genetic effects
and changing environmental factors.
What are some of the challenges that will likely emerge from
such a system? We suggest that there will be several areas
that will be of immediate concern. The first is undesired
presymptomatic diagnosis or knowledge of reproductive
risk. Another important challenge is that there will initially
be a great deal of uncertainty in the interpretation of genetic
information because the penetrance of deleterious alleles in
the general population is unknown. If genetic screening is
most inexpensively carried out using very broad tools, there
will inevitably be loss of autonomy in the choice to test for
certain diseases and decline testing of others. Finally, one
could imagine that there could be active harm caused by
genetic testing. Personal data could be utilized in ways that
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discrimination, forensic analyses, or even identity theft.
These challenges are real and need to be responsibly managed
at the institutional, national, and international levels.
Yet, this type of system for managing genetic information in
the EHR must be developed if there is any hope of wide-
spread clinical integration of genomic data. Already,
consumer-directed health networks, such as Google Health,
are enabling consumers to collect, store, manage, and
control access to various types of medical information [18].
It will not be long before these internet-based information
tools incorporate genome-wide data that can be easily mined
for their clinical significance over time as additional infor-
mation is collected. Without this, attempts to counsel
patients on the basis of genomic information will be futile.
A Ab bb br re ev vi ia at ti io on ns s
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